Small biotech faces a crossroad

After fifteen years and $157 million in R&D expenses, Alseres execs say they are on to "one of the great miracles of science," according to this profile in the Boston Globe. Or not. Reorganized with new executives and a new financing round close to four years ago, Alseres has attracted considerable attention for two experimental drugs--Cethrin and Inosine. Cethrin hopefully blocks an enzyme that prevents the growth of new nerve fibers after a spinal column injury and Inosine, in animal tests, has stimulated brain rewiring after a stroke. In the meantime, the Globe piece notes, CEO Peter Savas has been taking home a handsome salary--$1.1 million last year in total compensation--while his company's future hinges on the near-term success of one of these drugs.

- read the article from The Boston Globe

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."